12:00 AM
May 20, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oncotype DX prostate cancer assay: Additional data

Genomic Health and researchers at the University of California, San Francisco, reported additional data from a clinical validation study in 395 patients with early stage prostate cancer showing that the Oncotype DX Genomic Prostate Score (GPS) significantly increased the number of patients identified as having very low risk disease and thus were appropriate for active surveillance to 26% from 5-10% using clinical measures alone. Specifically, >33% of...

Read the full 314 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >